Mirae Asset Global ETFs Holdings’s Tourmaline Bio TRML Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,063	Closed	-$386K	–	3168
2025 Q3	$386K	Sell	8,063 -2,358	-23%	-$65.4K	﹤0.01%	1992
2025 Q2	$167K	Sell	10,421 -3,379	-24%	-$54.7K	﹤0.01%	2375
2025 Q1	$210K	Sell	13,800 -578	-4%	-$9.27K	﹤0.01%	2298
2024 Q4	$291K	Buy	14,378 +1,598	+13%	+$40.2K	﹤0.01%	2192
2024 Q3	$329K	Buy	+12,780	New	+$213K	﹤0.01%	2121

Mirae Asset Global ETFs Holdings's TRML Position: Q4 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 8,063 shares — an estimated $386K sold.

Mirae Asset Global ETFs Holdings first reported a position in TRML in Q3 2024 and held it in 5 quarters. The position peaked at $386K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Mirae Asset Global ETFs Holdings reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Mirae Asset Global ETFs Holdings sold 8,063 Tourmaline Bio shares in Q4 2025, an estimated $386K.
Mirae Asset Global ETFs Holdings first reported a position in Tourmaline Bio in Q3 2024 and held it in 5 quarters.
Mirae Asset Global ETFs Holdings's Tourmaline Bio position peaked at $386K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.